All Trials

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with hormone-sensitive oligometastatic prostate adenocarcinoma (1–3 SBRT-amenable lesions; prior definitive therapy; testosterone >125 ng/dL; PSA 0.5–50; PSADT <15 months; ECOG 0–2) receive metastasis-directed SBRT plus adenosine-axis modulation with quemliclustat (CD73 inhibitor) and etrumadenant (A2A/A2B receptor antagonist) followed by PD-1 blockade with zimberelimab. Aims to improve biochemical and radiographic control versus historical SBRT alone while deferring ADT.

ClinicalTrials.gov ID: NCT05915442

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: ARPI‑naïve men with metastatic castration‑resistant or hormone‑sensitive prostate cancer (plus a Japanese safety cohort) receive long‑acting intramuscular abiraterone decanoate (ASP5541), a CYP17A1 inhibitor prodrug dosed about every 12 weeks, with or without prednisone/prednisolone, compared against standard daily oral abiraterone acetate with corticosteroid. Key comparisons include PSA responses in mCRPC and activity/safety (including mineralocorticoid toxicity) in mHSPC.

ClinicalTrials.gov ID: NCT07005154

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: PSMA‑positive mCRPC after progression on ≥12 weeks of an ARPI, ECOG 0–2, and adequate organ function; excludes prior PSMA‑targeted therapy, recent radioisotopes, PARP inhibitors, and chemotherapy for mCRPC (docetaxel in mCSPC allowed). Randomizes to 177Lu‑TLX591 (rosopatamab tetraxetan), a PSMA‑targeted beta‑emitting radioimmunotherapy, plus SOC (enzalutamide, abiraterone/prednisone, or docetaxel/prednisone) versus SOC alone.

ClinicalTrials.gov ID: NCT06520345

PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with radiographic mCRPC who have progressed after 177Lu‑PSMA‑617 receive oral zanzalintinib (XL092) monotherapy once daily. XL092 is an investigational multikinase TKI targeting VEGFR2, MET, and TAM kinases (TYRO3/AXL/MER) to inhibit angiogenesis and tumor growth; primary endpoint is 16‑week disease control.

ClinicalTrials.gov ID: NCT06568562

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with mCRPC who have progressed on abiraterone (without prior enzalutamide/apalutamide/darolutamide or recent radionuclide therapy) receive enzalutamide plus SX-682, an oral CXCR1/2 inhibitor that blocks MDSC trafficking to modulate the tumor microenvironment. Key exclusions include liver metastases, significant CV disease, active autoimmune/infectious disease, and use of strong CYP3A4 modulators or QT‑prolonging drugs.

ClinicalTrials.gov ID: NCT06228053

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult men with high‑volume metastatic hormone‑sensitive prostate adenocarcinoma (ECOG 0–2, castrate testosterone) are randomized to luxdegalutamide (JSB462), an oral PROTAC androgen receptor degrader, plus abiraterone (two dose levels) versus standard ARPI therapy (abiraterone or enzalutamide). Prior second‑generation ARPI for advanced/metastatic disease is excluded; limited prior (neo)adjuvant therapy allowed if completed >12 months before randomization.

ClinicalTrials.gov ID: NCT06991556

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (Grade 1–3) unresectable or metastatic pancreatic or extra-pancreatic NETs with recent RECIST-defined progression and no prior VEGFR TKI or mTOR inhibitor are randomized to zanzalintinib (XL092, an oral multi-kinase inhibitor of VEGFR2/MET/TAM) versus everolimus. Excludes NECs and select NET subtypes; primary endpoint is PFS by blinded central review.

ClinicalTrials.gov ID: NCT06943755

A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic, microsatellite-stable pancreatic ductal adenocarcinoma that has progressed on at least one prior systemic therapy receive SBRT to selected lesion(s) followed by dual checkpoint blockade with botensilimab (Fc‑enhanced anti–CTLA‑4) plus balstilimab (anti–PD‑1). Eligible patients require ECOG 0–1, measurable disease, adequate organ function, ≤25% liver tumor burden, and no active CNS metastases or significant autoimmune/immunosuppression.

ClinicalTrials.gov ID: NCT06843551

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ersodetug in Patients With Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (tHI)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with tumor-associated hyperinsulinism—either insulin-secreting tumors or IGF‑2–mediated NICT—with refractory hypoglycemia despite standard therapies; ambulatory ICT patients are randomized to ersodetug (RZ358) 9 mg/kg IV plus standard care vs placebo, while hospitalized ICT/NICT and ambulatory IGF‑secreting tumor patients receive open‑label ersodetug. Ersodetug is a fully human monoclonal antibody that negatively allosterically modulates the insulin receptor to attenuate excessive insulin/IGF‑2 signaling to reduce hypoglycemia.

ClinicalTrials.gov ID: NCT06881992

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: First-line trial in adults with unresectable/advanced HCC (BCLC B not LRT-eligible or C; Child-Pugh A; ECOG 0–1; no prior systemic therapy) comparing rilvegostomig (PD-1/TIGIT bispecific) plus bevacizumab with or without tremelimumab (CTLA-4) versus standard atezolizumab (PD-L1) plus bevacizumab. Excludes significant bleeding risk/anticoagulation needs, active autoimmune disease requiring immunosuppression, CNS mets, hepatic encephalopathy, and prior anti-CTLA-4/TIGIT.

ClinicalTrials.gov ID: NCT06921785